Live from the NIH registry
Studies recruiting near Lancaster right now
Top 25 of 434 recruiting studies, sorted by proximity — each links to its official registry page
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Ephrata Cancer Center — Ephrata, Pennsylvania (11.5 mi)
· Sponsor: SWOG Cancer Research Network
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Penn State Children's Hospital — Hershey, Pennsylvania (25.0 mi)
· Sponsor: National Cancer Institute (NCI)
Observational Study Protocol: LIVER-R
Hepatobiliary Cancers
N/A
Observational 4,490 participants sought
Research Site — Lancaster, Pennsylvania (0.4 mi)
· Sponsor: AstraZeneca
Transitional Care Program for Fluid Overload in Cirrhosis
Cirrhosis, Liver
N/A
Interventional 20 participants sought
Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania (25.0 mi)
· Sponsor: Milton S. Hershey Medical Center
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
Phase 3
Interventional 600 participants sought
Research Site — Hershey, Pennsylvania (25.0 mi)
· Sponsor: AstraZeneca
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
Phase 3
Interventional 450 participants sought
Lancaster General Hospital - Ann B Barshinger Cancer Institute — Lancaster, Pennsylvania (0.4 mi)
· Sponsor: Eli Lilly and Company
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Narcolepsy Type 1
Phase 3
Interventional 150 participants sought
Alkermes Investigational Site — Wyomissing, Pennsylvania (26.6 mi)
· Sponsor: Alkermes, Inc.
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Bladder Carcinoma, Ureter Carcinoma
N/A
Observational 2,020 participants sought
Cancer Care Associates of York — York, Pennsylvania (23.2 mi)
· Sponsor: Guardant Health, Inc.
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer
Phase 3
Interventional 1,000 participants sought
The Centers for Advanced Urology d/b/a Keystone Urology Specialist — Lancaster, Pennsylvania (0.4 mi)
· Sponsor: Pfizer
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
Transitional Cell Cancer of Renal Pelvis and Ureter
Phase 3
Interventional 100 participants sought
The Pennsylvania State University (Penn State) Milton S. Hershey Medical Center — Hershey, Pennsylvania (25.0 mi)
· Sponsor: Steba Biotech S.A.
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 3
Interventional 1,200 participants sought
Cancer Care Associates Of York ( Site 0005) — York, Pennsylvania (23.2 mi)
· Sponsor: Merck Sharp & Dohme LLC
Multi-Center Clean Air Randomized Controlled Trial in COPD
Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Interventional 770 participants sought
Reading Hospital — West Reading, Pennsylvania (27.5 mi)
· Sponsor: JHSPH Center for Clinical Trials
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Phase 4
Interventional 6,000 participants sought
Penn Lancaster General Health Research Institute — Lancaster, Pennsylvania (0.4 mi)
· Sponsor: Duke University
Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)
Peripheral Nerve Injuries
Phase 2
Interventional 40 participants sought
Wellspan Health — York, Pennsylvania (23.2 mi)
· Sponsor: Major Extremity Trauma Research Consortium
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Phase 3
Interventional 1,530 participants sought
Cancer Care Associates Of York ( Site 9517) — York, Pennsylvania (23.2 mi)
· Sponsor: Merck Sharp & Dohme LLC
E-Mindfulness Approaches for Living After Breast Cancer
Breast Cancer, Depression
Phase 3
Interventional 402 participants sought
Lancaster General Ann B Barshinger Cancer Institute — Lancaster, Pennsylvania (0.4 mi)
· Sponsor: NRG Oncology
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Neuroblastoma
Phase 2
Interventional 93 participants sought
Penn State Milton S. Hershey Medical Center and Children's Hospital — Hershey, Pennsylvania (25.0 mi)
· Sponsor: Giselle Sholler
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)
Idiopathic Hypersomnia
Phase 3
Interventional 248 participants sought
Respiratory Specialists — Wyomissing, Pennsylvania (26.6 mi)
· Sponsor: Harmony Biosciences Management, Inc.
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Cardiovascular Disease and Lipoprotein(a)
Phase 3
Interventional 5,700 participants sought
Lancaster General Health — Lancaster, Pennsylvania (0.4 mi)
· Sponsor: Novartis Pharmaceuticals
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Phase 2
Interventional 2,000 participants sought
Penn State Milton S Hershey Medical Center — Hershey, Pennsylvania (25.0 mi)
· Sponsor: National Cancer Institute (NCI)
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
Cystic Fibrosis
N/A
Observational 400 participants sought
Hershey Medical Center Pennsylvania State University — Hershey, Pennsylvania (25.0 mi)
· Sponsor: Nicole Hamblett
Development of a College Student-Delivered Cognitive-Behavioral Therapy (CBT) Intervention for Rural High School Students
Depression, Anxiety
N/A
Interventional 40 participants sought
Penn State College of Medicine — Hershey, Pennsylvania (25.0 mi)
· Sponsor: Milton S. Hershey Medical Center
Clinical Evaluation of Precision for the Potassium and Ionized Calcium Tests in Capillary Specimens
Hematologic Tests
N/A
Interventional 425 participants sought
Penn State Health Milton S. Hershey Medical Center (Hershey) — Hershey, Pennsylvania (25.0 mi)
· Sponsor: Abbott Point of Care
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Phase 3
Interventional 1,875 participants sought
Penn State Children's Hospital — Hershey, Pennsylvania (25.0 mi)
· Sponsor: National Cancer Institute (NCI)
Use of Nicotine Pouches Among Daily Smokers
Tobacco Dependence
N/A
Interventional 375 participants sought
Penn State College of Medicine — Hershey, Pennsylvania (25.0 mi)
· Sponsor: Milton S. Hershey Medical Center